NASDAQ:ABEO Abeona Therapeutics (ABEO) News Today $4.00 -0.03 (-0.74%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$3.72▼$4.2050-Day Range$2.76▼$4.0352-Week Range$2.19▼$6.13Volume202,898 shsAverage Volume136,305 shsMarket Capitalization$75.12 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Media Mentions By Week ABEO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABEO News Sentiment▼0.460.52▲Average Medical News Sentiment ABEO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABEO Articles This Week▼41▲ABEO Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAbeona Therapeutics Inc (NASDAQ:ABEO) Expected to Post Q2 2023 Earnings of ($0.66) Per Shareamericanbankingnews.com - June 2 at 7:25 AMABEO: Additional Phase 3 VIITAL™ Data Presented at ISID Meetingmsn.com - May 30 at 2:30 PMABEO: Additional Phase 3 VIITAL™ Data Presented at ISID Meetingfinance.yahoo.com - May 30 at 2:30 PMAbeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Updateamericanbankingnews.com - May 29 at 1:40 AMQ1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Callfinance.yahoo.com - May 25 at 8:33 AMAbeona Therapeutics Q1 2023 Earnings Previewseekingalpha.com - May 23 at 4:00 PMAbeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023finance.yahoo.com - May 22 at 8:13 AMAbeona Therapeutics (ABEO) Set to Announce Quarterly Earnings on Tuesdayamericanbankingnews.com - May 22 at 7:50 AMAbeona Therapeutics (NASDAQ:ABEO) Now Covered by Analysts at StockNews.comamericanbankingnews.com - May 19 at 6:54 AMAbeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)finance.yahoo.com - May 16 at 4:56 PMShort Interest in Abeona Therapeutics Inc (NASDAQ:ABEO) Decreases By 14.8%americanbankingnews.com - May 14 at 6:00 AMAbeona Therapeutics First Quarter 2023 Earnings: US$0.54 loss per share (vs US$3.59 loss in 1Q 2022)finance.yahoo.com - May 13 at 12:57 PMAbeona stock rises on new data for rare skin disorder drug EB-101msn.com - May 12 at 9:36 AMAbeona Therapeutics Inc.: Abeona Therapeutics Reports First Quarter 2023 Financial Resultsfinanznachrichten.de - May 11 at 8:33 AMAbeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meetingfinance.yahoo.com - May 11 at 8:33 AMAbeona Therapeutics Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 8:33 AMAbeona Therapeutics (NASDAQ:ABEO) vs. Nurix Therapeutics (NASDAQ:NRIX) Critical Comparisonamericanbankingnews.com - May 11 at 4:26 AMAbeona Therapeutics (ABEO) Scheduled to Post Quarterly Earnings on Thursdayamericanbankingnews.com - May 10 at 8:44 AMAbeona Therapeutics (ABEO) Set to Announce Quarterly Earnings on Thursdayamericanbankingnews.com - May 10 at 8:02 AMAntimicrobial Peptides Market Size and volume sale report 2023marketwatch.com - May 5 at 7:49 PMShort Interest in Abeona Therapeutics Inc (NASDAQ:ABEO) Drops By 19.9%americanbankingnews.com - April 30 at 5:58 AMIntracranial Therapeutic Market Size By 2030marketwatch.com - April 28 at 1:18 PMZacks Small Cap Comments on Abeona Therapeutics Inc's Q1 2023 Earnings (NASDAQ:ABEO)americanbankingnews.com - April 23 at 1:40 AMAbeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Growth in Short Interestamericanbankingnews.com - April 19 at 7:22 AMABEO: Initiating Coverage of Abeona Therapeutics Inc.; Using Gene Therapy to Treat Orphan Diseases…finance.yahoo.com - April 18 at 1:10 PMAbeona Therapeutics Announces Multiple Abstracts Accepted from itstmcnet.com - April 10 at 10:42 AMAbeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)finance.yahoo.com - April 10 at 10:42 AMAlpha-1 Antitrypsin Drugs Market Forecast to 2030marketwatch.com - April 7 at 8:40 AMABEO Abeona Therapeutics Inc.seekingalpha.com - March 31 at 6:45 PMCompanies Like Abeona Therapeutics (NASDAQ:ABEO) Could Be Quite Riskyfinance.yahoo.com - March 31 at 8:00 AMAbeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 29 at 2:00 PMAbeona Therapeutics GAAP EPS of -$5.53 misses by $1.61, revenue of $1.41M misses by $0.91Mmsn.com - March 29 at 8:59 AMAbeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 29 at 8:59 AMAbeona Therapeutics (ABEO) to Release Earnings on Wednesdayamericanbankingnews.com - March 28 at 9:02 AMAntimicrobial Peptides Market Size 2023 | Dynamics, Supply-Demand and Growth Rate Analysis by 2028marketwatch.com - March 27 at 12:25 PMAbeona Therapeutics (NASDAQ:ABEO) Shares Cross Above 50-Day Moving Average of $2.54americanbankingnews.com - March 26 at 7:22 AMAbeona Therapeutics Announces New Employee Inducement Grantsfinance.yahoo.com - March 24 at 8:00 AMAntimicrobial Peptides Market: The Growing Trend 2030marketwatch.com - March 21 at 3:46 PMAbeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meetingfinance.yahoo.com - March 16 at 8:07 AMPolymer Drug Conjugates Market Application, Product, Sales and Forecast 2023-2028marketwatch.com - March 15 at 8:27 AMAbeona Therapeutics Announces Update on AAV Ophthalmology Programfinance.yahoo.com - March 14 at 10:43 AMGlobal Alpha 1 Antitrypsin Deficiency Treatment Market 2023 Revenue, Competitive Dynamics, Advancement, and Forecast to 2030 By VMReportsmarketwatch.com - March 10 at 5:42 AMAlpha-1 Antitrypsin Drugs New Investments Expected to Boost the Demand by 2028marketwatch.com - March 3 at 3:46 PM2023 Latest Genetic Modification Therapies Market Research: Pricing Strategy and Analysis for PRODUCT TYPE by 2028marketwatch.com - February 23 at 8:08 AMGenetic Chronic Obstructive Pulmonary Disease (COPD) Market to Surpass US$ 720.5 Million by 2030, Says Coherent Market Insights (CMI)finance.yahoo.com - February 20 at 10:20 AMAlpha-1 Antitrypsin Drugs Market by Top Manufacturers, Growing Demand and Supply 2023-2028marketwatch.com - February 18 at 9:18 AMPolymer Drug Conjugates Market Massive Growth Strikes Due To Technological Innovation During 2023-2028marketwatch.com - February 14 at 8:27 AMMucopolysaccharidosis Therapeutics Market 2023 Assessed to See Remarkable Growth till 2028 | Says Absolute Reports Expertsmarketwatch.com - February 14 at 8:27 AMAlpha 1 Antitrypsin Deficiency Treatment Market Latest Research Report with Growth Projection and top Industry Analysis 2023-2028marketwatch.com - February 7 at 8:06 AMAlpha-1 Antitrypsin Drugs Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028marketwatch.com - January 26 at 1:55 AM Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Adagene News LifeVantage News Galecto News Gain Therapeutics News Lantern Pharma News Homology Medicines News IO Biotech News Enochian Biosciences News Connect Biopharma News Anebulo Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:ABEO) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.